Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 437348, 17 pages
Review Article

Novel Immunotherapeutic Strategies of Gastric Cancer Treatment

1Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
2Department of Biomedicine, Azienda Ospedaliera Universitaria Careggi, Viale Morgagni 85, 50134 Florence, Italy

Received 2 August 2011; Accepted 26 September 2011

Academic Editor: Walter J. Storkus

Copyright © 2011 Amedeo Amedei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Gastric cancer (GC) is the fourth most common cancer and the second most frequent cause of cancer-related deaths, accounting for 10.4% of cancer deaths worldwide. Despite the improvements, estimated cure rates for patients with advanced stages remain poor, and in the metastatic setting, chemotherapy is the mainstay of palliative therapy and results in objective response rates (ORRs) of only 20–40% and median overall survivals (OS) of 8–10 months. Therefore, many investigators believe that the potential for making significant progress lies in understanding and exploiting the molecular biology of these tumors to investigate new therapeutic strategies to combat GC, such as specific immunotherapy. In this paper, we analyze the different approaches used for immune-based (especially dendritic and T cells) therapies to gastric cancer treatment and discuss the results obtained in preclinical models as in clinical trials.